INNOVOTEX INC. has raised $750K in a Seed round, a capital infusion aimed at advancing its work on Macrocycle Drug Conjugates (MDCs), a therapeutic platform the company says could improve how cancer drugs reach and stay inside tumors.
The pharmaceutical startup’s lead candidate, NOVO-111, is designed to tackle persistent limitations in oncology by boosting therapeutic exposure and durability at the tumor site. The round’s investors were not disclosed, but the funding gives INNOVOTEX runway to push its novel approach forward.














